Trials / Completed
CompletedNCT00338884
Safety And Effectiveness Of Daily Dosing With 37.5 mg Sunitinib Malate In Patients With Advanced Kidney Cancer
A Phase II Efficacy And Safety Study Of Sunitinib Malate (SU011248) Administered In A Continuous Daily Regimen In Patients With Advanced (First-Line) Renal Cell Cancer
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 120 (actual)
- Sponsor
- Pfizer · Industry
- Sex
- All
- Age
- —
- Healthy volunteers
- Not accepted
Summary
A phase II study to allow patients with advanced kidney cancer access to sunitinib malate treatment and to find out the good and bad effects of taking 37.5 mg sunitinib malate in a continuous daily regimen (once per day) for one year.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Sunitinib malate | Sunitinib malate starting dose 37.5 mg daily continuous daily schedule |
Timeline
- Start date
- 2006-09-01
- Primary completion
- 2009-04-01
- Completion
- 2009-04-01
- First posted
- 2006-06-20
- Last updated
- 2012-08-31
- Results posted
- 2011-06-14
Locations
15 sites across 6 countries: Argentina, Australia, Brazil, Mexico, South Korea, Taiwan
Source: ClinicalTrials.gov record NCT00338884. Inclusion in this directory is not an endorsement.